Gilead Sciences (GILD) 116.25 $GILD
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - 11 mins ago
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 3.35 (unch), KNMD: (), VTAE: 9.81 (-0.09), LLY: 84.93 (-0.75), OMER: 16.09 (-0.27), JNJ: 99.87 (+0.85), ISIS: 52.76 (-1.64), OPK: 16.64 (-0.20), GILD: 116.25 (+3.18), AZN: 32.84 (+0.03), MRK: 58.67 (+1.15), CCXI: 8.57 (-0.05), VBLT: 6.13 (-0.02), NVS: 103.79 (+1.00)
Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - 12 mins ago
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 116.25 (+3.18), AMGN: 170.66 (-2.08), ABBV: 71.27 (+0.04), CELG: 133.40 (-2.02)
Stocks Extend Modest Gains as Crude Oil Tops $49
at The Street - 24 mins ago
Stocks extend modest gains Wednesday after a steeper-than-expected drop in crude supplies prompts a surge in oil prices.
GILD: 116.25 (+3.18), COP: 52.81 (+0.57), YELP: 24.15 (-9.36), TWTR: 31.75 (-4.79), MA: 95.85 (+0.69), HUM: 183.27 (-1.25)
Stocks Turn Positive as Crude Inventories Drop
at The Street - 1 hr 51 mins ago
Stocks turn positive on Wednesday after a steeper-than-expected drop in crude supplies.
ANTM: 154.30 (+0.10), GILD: 116.25 (+3.18), YELP: 24.15 (-9.36), TWTR: 31.75 (-4.79), MA: 95.85 (+0.69), HUM: 183.27 (-1.25)
Cramer -- Gilead Has a ‘Fabulous’ Quarter, Tons of Merger Opportunities
at The Street - 2 hrs 6 mins ago
Gilead Sciences not only beat earnings estimates but it can make a massive acquisition should it want to do so, Cramer says.
GILD: 116.25 (+3.18), XBI: 252.33 (-6.61), IBB: 376.70 (-6.14)
Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - 2 hrs 31 mins ago
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 310.08 (-9.85), F: 15.09 (+0.26), RIG: 14.27 (+0.15), GILD: 116.25 (+3.18), PFE: 35.67 (+0.32), COP: 52.81 (+0.57), XOM: 82.54 (+0.06), AMGN: 170.66 (-2.08), DD: 56.16 (+0.26), CVX: 92.69 (+0.29), SLB: 83.35 (+0.85), UPS: 101.52 (+1.58), CELG: 133.40 (-2.02)
Amp Up Your Portfolio With These Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 29, 8:41AM CDT
Source: Flickr user Stockmonkeys.com. Biotech stocks have been among the market's brightest shining stars, but many of these stocks have already made big moves higher. As a result, investors could be wondering if there are any companies in the...
GILD: 116.25 (+3.18), CELG: 133.40 (-2.02)
Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 8:40AM CDT
Gilead Sciences, Inc.'s (GILD) second-quarter earnings (including stock-based compensation expenses) of $3.10 per share surpassed the Zacks Consensus Estimate of $2.83.
GILD: 116.25 (+3.18), LGND: 103.22 (-2.62), ABBV: 71.27 (+0.04), ANAC: 147.67 (-3.64)
Lithia Motors, Qualcomm, Twitter, Gilead and Facebook highlighted as Zacks Bull and Bear of the Day - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 8:30AM CDT
Lithia Motors, Qualcomm, Twitter, Gilead and Facebook highlighted as Zacks Bull and Bear of the Day
LAD: 115.98 (+3.39), GILD: 116.25 (+3.18), FB: 95.70 (+0.41), QCOM: 63.08 (-0.02), TWTR: 31.75 (-4.79)
Gilead Sciences (GILD) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Wed Jul 29, 8:04AM CDT
The following Gilead Sciences (GILD) conference call took place on July 28, 2015, 04:30 PM ET. This is a transcript of that earnings call:
GILD: 116.25 (+3.18)
Stock Futures Gain Ahead of Fed Rates Announcement
at The Street - Wed Jul 29, 7:22AM CDT
Stock futures look to extend Tuesday's surge in equities as investors await an announcement from the Federal Reserve Wednesday afternoon.
ANTM: 154.30 (+0.10), GILD: 116.25 (+3.18), CYT: 73.85 (+15.46), YELP: 24.15 (-9.36), TWTR: 31.75 (-4.79), CVX: 92.69 (+0.29), MA: 95.85 (+0.69), HUM: 183.27 (-1.25)
Gilead Sciences posts higher net income of USD4.5bn in Q2 2015
M2 - Wed Jul 29, 4:29AM CDT
Biopharmaceutical company Gilead Sciences (Nasdaq:GILD) disclosed on Tuesday that its net income was USD4.5bn (USD2.92 per diluted share) for the second quarter ended 30 June 2015.
GILD: 116.25 (+3.18)
Gilead Sciences to pay dividend to holders of record of 16 September 2015
M2 - Wed Jul 29, 4:19AM CDT
The board of directors of Gilead Sciences (Nasdaq:GILD) on Tuesday declared a dividend of USD0.43 per share of the company's common stock for the third quarter of 2015.
GILD: 116.25 (+3.18)
5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen
at Investor's Business Daily - Tue Jul 28, 7:07PM CDT
Biotechs, generic-drug makers and ethical-drug makers are some of the highest-ranked industry groups among the 197 that IBD tracks, and with recent view-topping earnings reports, FDA approvals and strategic divestments, they're proving their...
MNK: 123.97 (+0.10), AGN: 336.60 (-2.90), GILD: 116.25 (+3.18), JAZZ: 189.24 (-3.78), TEVA: 71.06 (-0.35), SNY: 53.83 (+0.02), REGN: 540.83 (-11.62)
Gilead beats Street 2Q forecasts on surge in sales, profit
By LINDA A. JOHNSON - AP - Tue Jul 28, 5:47PM CDT
Blockbuster hepatitis C medicine Harvoni propelled Gilead Sciences Inc.'s second-quarter profit up 23 percent as total revenue for the biotech drugmaker jumped 26 percent and it raised its 2015 sales forecast for the second time. Its shares jumped in after-hours trading.
1 Comment
GILD: 116.25 (+3.18), MRK: 58.67 (+1.15), BMY: 64.40 (-0.26)
Twitter Q2 Earnings Turns After-hours Rollercoaster - Analyst Blog
Mark Vickery - Zacks Investment Research - Tue Jul 28, 4:36PM CDT
Social media staple Twitter (TWTR) beat Q2 earnings and revenues after the bell Tuesday, and its share price spiked immediately in after-hours trading. But then...
GILD: 116.25 (+3.18), TWTR: 31.75 (-4.79)
Gilead Sciences Inc. Posts Q2 Results, Able to Beat Earnings, Revenue Estimates - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Jul 28, 4:20PM CDT
Gilead Sciences posted its financial results for the second quarter of 2015 and was able to beat previous estimates for the company's earnings and revenues for the quarter.
GILD: 116.25 (+3.18)
Gilead Sciences Inc. Q2 Earnings: Harvoni Delivers Again
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 28, 4:19PM CDT
Source: Gilead Sciences. A few days ago, I suggested that there were three scenarios that could potentially unfold with Gilead Sciences ' second-quarter results -- high fives, ho-hum, or heave-ho. The big biotech announced those results after...
GILD: 116.25 (+3.18)
Stocks Post First Gain In 6 Days; Twitter, Gilead Leap On Earnings
at Investor's Business Daily - Tue Jul 28, 3:57PM CDT
Stocks regained their footing Tuesday after a five-day decline as volume picked up on both exchanges, according to preliminary data. The Nasdaq rose 1%; the S&P 500 gained 1.2%; and the Dow Jones industrial average moved 1.1% higher in the stock...
GILD: 116.25 (+3.18), AKAM: 70.01 (-3.64), BWLD: 193.59 (+22.31), TWTR: 31.75 (-4.79), MA: 95.85 (+0.69)
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - 11 mins ago
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 3.35 (unch), KNMD: (), VTAE: 9.81 (-0.09), LLY: 84.93 (-0.75), OMER: 16.09 (-0.27), JNJ: 99.87 (+0.85), ISIS: 52.76 (-1.64), OPK: 16.64 (-0.20), GILD: 116.25 (+3.18), AZN: 32.84 (+0.03), MRK: 58.67 (+1.15), CCXI: 8.57 (-0.05), VBLT: 6.13 (-0.02), NVS: 103.79 (+1.00)
Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - 12 mins ago
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 116.25 (+3.18), AMGN: 170.66 (-2.08), ABBV: 71.27 (+0.04), CELG: 133.40 (-2.02)
Stocks Extend Modest Gains as Crude Oil Tops $49
at The Street - 24 mins ago
Stocks extend modest gains Wednesday after a steeper-than-expected drop in crude supplies prompts a surge in oil prices.
GILD: 116.25 (+3.18), COP: 52.81 (+0.57), YELP: 24.15 (-9.36), TWTR: 31.75 (-4.79), MA: 95.85 (+0.69), HUM: 183.27 (-1.25)
Stocks Turn Positive as Crude Inventories Drop
at The Street - 1 hr 51 mins ago
Stocks turn positive on Wednesday after a steeper-than-expected drop in crude supplies.
ANTM: 154.30 (+0.10), GILD: 116.25 (+3.18), YELP: 24.15 (-9.36), TWTR: 31.75 (-4.79), MA: 95.85 (+0.69), HUM: 183.27 (-1.25)
Cramer -- Gilead Has a ‘Fabulous’ Quarter, Tons of Merger Opportunities
at The Street - 2 hrs 6 mins ago
Gilead Sciences not only beat earnings estimates but it can make a massive acquisition should it want to do so, Cramer says.
GILD: 116.25 (+3.18), XBI: 252.33 (-6.61), IBB: 376.70 (-6.14)
Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - 2 hrs 31 mins ago
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 310.08 (-9.85), F: 15.09 (+0.26), RIG: 14.27 (+0.15), GILD: 116.25 (+3.18), PFE: 35.67 (+0.32), COP: 52.81 (+0.57), XOM: 82.54 (+0.06), AMGN: 170.66 (-2.08), DD: 56.16 (+0.26), CVX: 92.69 (+0.29), SLB: 83.35 (+0.85), UPS: 101.52 (+1.58), CELG: 133.40 (-2.02)
Amp Up Your Portfolio With These Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 29, 8:41AM CDT
Source: Flickr user Stockmonkeys.com. Biotech stocks have been among the market's brightest shining stars, but many of these stocks have already made big moves higher. As a result, investors could be wondering if there are any companies in the...
GILD: 116.25 (+3.18), CELG: 133.40 (-2.02)
Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 8:40AM CDT
Gilead Sciences, Inc.'s (GILD) second-quarter earnings (including stock-based compensation expenses) of $3.10 per share surpassed the Zacks Consensus Estimate of $2.83.
GILD: 116.25 (+3.18), LGND: 103.22 (-2.62), ABBV: 71.27 (+0.04), ANAC: 147.67 (-3.64)
Lithia Motors, Qualcomm, Twitter, Gilead and Facebook highlighted as Zacks Bull and Bear of the Day - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 8:30AM CDT
Lithia Motors, Qualcomm, Twitter, Gilead and Facebook highlighted as Zacks Bull and Bear of the Day
LAD: 115.98 (+3.39), GILD: 116.25 (+3.18), FB: 95.70 (+0.41), QCOM: 63.08 (-0.02), TWTR: 31.75 (-4.79)
Gilead Sciences (GILD) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Wed Jul 29, 8:04AM CDT
The following Gilead Sciences (GILD) conference call took place on July 28, 2015, 04:30 PM ET. This is a transcript of that earnings call:
GILD: 116.25 (+3.18)
Stock Futures Gain Ahead of Fed Rates Announcement
at The Street - Wed Jul 29, 7:22AM CDT
Stock futures look to extend Tuesday's surge in equities as investors await an announcement from the Federal Reserve Wednesday afternoon.
ANTM: 154.30 (+0.10), GILD: 116.25 (+3.18), CYT: 73.85 (+15.46), YELP: 24.15 (-9.36), TWTR: 31.75 (-4.79), CVX: 92.69 (+0.29), MA: 95.85 (+0.69), HUM: 183.27 (-1.25)
Gilead Sciences posts higher net income of USD4.5bn in Q2 2015
M2 - Wed Jul 29, 4:29AM CDT
Biopharmaceutical company Gilead Sciences (Nasdaq:GILD) disclosed on Tuesday that its net income was USD4.5bn (USD2.92 per diluted share) for the second quarter ended 30 June 2015.
GILD: 116.25 (+3.18)
Gilead Sciences to pay dividend to holders of record of 16 September 2015
M2 - Wed Jul 29, 4:19AM CDT
The board of directors of Gilead Sciences (Nasdaq:GILD) on Tuesday declared a dividend of USD0.43 per share of the company's common stock for the third quarter of 2015.
GILD: 116.25 (+3.18)
5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen
at Investor's Business Daily - Tue Jul 28, 7:07PM CDT
Biotechs, generic-drug makers and ethical-drug makers are some of the highest-ranked industry groups among the 197 that IBD tracks, and with recent view-topping earnings reports, FDA approvals and strategic divestments, they're proving their...
MNK: 123.97 (+0.10), AGN: 336.60 (-2.90), GILD: 116.25 (+3.18), JAZZ: 189.24 (-3.78), TEVA: 71.06 (-0.35), SNY: 53.83 (+0.02), REGN: 540.83 (-11.62)
Gilead beats Street 2Q forecasts on surge in sales, profit
By LINDA A. JOHNSON - AP - Tue Jul 28, 5:47PM CDT
Blockbuster hepatitis C medicine Harvoni propelled Gilead Sciences Inc.'s second-quarter profit up 23 percent as total revenue for the biotech drugmaker jumped 26 percent and it raised its 2015 sales forecast for the second time. Its shares jumped in after-hours trading.
1 Comment
GILD: 116.25 (+3.18), MRK: 58.67 (+1.15), BMY: 64.40 (-0.26)
Twitter Q2 Earnings Turns After-hours Rollercoaster - Analyst Blog
Mark Vickery - Zacks Investment Research - Tue Jul 28, 4:36PM CDT
Social media staple Twitter (TWTR) beat Q2 earnings and revenues after the bell Tuesday, and its share price spiked immediately in after-hours trading. But then...
GILD: 116.25 (+3.18), TWTR: 31.75 (-4.79)
Gilead Sciences Inc. Posts Q2 Results, Able to Beat Earnings, Revenue Estimates - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Jul 28, 4:20PM CDT
Gilead Sciences posted its financial results for the second quarter of 2015 and was able to beat previous estimates for the company's earnings and revenues for the quarter.
GILD: 116.25 (+3.18)
Gilead Sciences Inc. Q2 Earnings: Harvoni Delivers Again
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 28, 4:19PM CDT
Source: Gilead Sciences. A few days ago, I suggested that there were three scenarios that could potentially unfold with Gilead Sciences ' second-quarter results -- high fives, ho-hum, or heave-ho. The big biotech announced those results after...
GILD: 116.25 (+3.18)
Stocks Post First Gain In 6 Days; Twitter, Gilead Leap On Earnings
at Investor's Business Daily - Tue Jul 28, 3:57PM CDT
Stocks regained their footing Tuesday after a five-day decline as volume picked up on both exchanges, according to preliminary data. The Nasdaq rose 1%; the S&P 500 gained 1.2%; and the Dow Jones industrial average moved 1.1% higher in the stock...
GILD: 116.25 (+3.18), AKAM: 70.01 (-3.64), BWLD: 193.59 (+22.31), TWTR: 31.75 (-4.79), MA: 95.85 (+0.69)
